Critique on “Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights” [Response to Letter]

"Critique on “Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights” [Response to Letter]." Pragmatic and Observational Research, , pp. 91–92

This article responds to:

Critique on “Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights” [Letter]

Disclosure

Tiago Biachi de Castria receives honoraria from Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme Corp., Ipsen, Moderna, AstraZeneca, and A2Bio. Richard D Kim receives honoraria from AstraZeneca, Exelixis, Ipsen, Eisai, Roche, and Pfizer (consulting/advisory role); and Incyte and AstraZeneca (speaker’s bureau). The authors report no other conflicts of interest in this communication.